

Bulletin from the Extraordinary General Meeting of PMD Device Solutions AB held on 3 April 2024

PMD Device Solutions AB (publ), held an extraordinary general meeting on Wednesday, 3 April 2024. The main resolutions passed at the meeting were as follows.

Election of new auditor

It was resolved to elect HLB Auditoriet AB as new auditing firm and Martin Gustafsson as new auditor with Mats-Åke Andersson as deputy auditor, for the period until the end of the next Annual General Meeting.

Determination of the remuneration to the auditor

It was resolved that the remuneration to the auditor shall be paid according to approved invoices.

Information about PMDS

PMDS develops and sells medical products for respiratory monitoring. Its primary product is RespiraSense™, a solution used for monitoring respiratory rate to detect deterioration of a patient's general condition early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense™ is, to the PMDS's knowledge, the world's only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. PMDS received FDA approval for RespiraSense™ in 2022. RespiraSense™ is a novel technology and today used in 25 hospitals across United Kingdom and Ireland. PMDS seeks to continue increasing its market share in the United Kingdom, with Germany and the United States to follow with initial market access activities.

For additional information, please contact

Myles Murray, CEO

Phone: +353 86 887 4994

E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com

The Company's Certified Adviser is Redeye.

For additional information, please contact

Myles Murray, CEO

Phone: +353 86 887 4994

E-mail: myles@pmd-solutions.com & for general enquiries investor.relations@pmd-solutions.com

The Company's Certified Adviser is Redeye.



PRESS RELEASE
03 April 2024 10:24:00 CEST

Information about PMDS

PMD Device Solutions AB develops and sells medical products for respiratory monitoring in both the hospital and homecare setting. Its primary product is RespiraSense, a solution used for monitoring respiratory rate to support the detection of patient deterioration early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense is, to the Company's knowledge, the world's only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. RespiraSense is a novel technology that is commercialised in Europe, the UK, and FDA cleared in the US. The company's shares are listed on Nasdaq First North Growth Market (STO: PMDS).

Attachments

Bulletin from the Extraordinary General Meeting of PMD Device Solutions AB held on 3 April 2024